About biogaia - BGLAF
BioGaia AB engages in the development, marketing, and sale of probiotic products. It operates through the following segments: Pediatrics, Adult Health, and Other. The Pediatrics segment sells drops, oral rehydration solutions, digestive health tablets, and also royalties pertaining to pediatric products. The Adult Health segment include gut health tablets, oral health products, and offers cultures as an ingredient in a licensee's dairy product. The Other segment consists royalties from the development projects, and revenue from packaging solutions. The company was founded by Jan Annwall and Peter Michael Rothschild in 1990 and is headquartered in Stockholm, Sweden.
BGLAF At a Glance
BioGaia AB
Kungsbroplan 3
Stockholm, Stockholm 112 27
| Phone | 46-8-555-293-00 | Revenue | 122.13M | |
| Industry | Pharmaceuticals: Other | Net Income | 34.42M | |
| Sector | Health Technology | 2023 Sales Growth | 11.954% | |
| Fiscal Year-end | 12 / 2024 | Employees | 210 | |
| View SEC Filings |
BGLAF Valuation
| P/E Current | 30.013 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 29.465 |
| Price to Sales Ratio | 8.303 |
| Price to Book Ratio | 5.033 |
| Price to Cash Flow Ratio | 25.272 |
| Enterprise Value to EBITDA | 19.731 |
| Enterprise Value to Sales | 7.056 |
| Total Debt to Enterprise Value | 0.001 |
BGLAF Efficiency
| Revenue/Employee | 581,562.80 |
| Income Per Employee | 163,882.876 |
| Receivables Turnover | 8.843 |
| Total Asset Turnover | 0.55 |
BGLAF Liquidity
| Current Ratio | 9.576 |
| Quick Ratio | 8.651 |
| Cash Ratio | 7.889 |
BGLAF Profitability
| Gross Margin | 72.808 |
| Operating Margin | 33.81 |
| Pretax Margin | 36.161 |
| Net Margin | 28.18 |
| Return on Assets | 15.502 |
| Return on Equity | 17.614 |
| Return on Total Capital | 17.009 |
| Return on Invested Capital | 17.614 |
BGLAF Capital Structure
| Total Debt to Total Equity | 0.433 |
| Total Debt to Total Capital | 0.432 |
| Total Debt to Total Assets | 0.377 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |